Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Net Margin (2016 - 2025)

Traws Pharma's Net Margin history spans 14 years, with the latest figure at 22.87% for Q2 2025.

  • Quarterly results put Net Margin at 22.87% for Q2 2025, up 3642275.0% from a year ago — trailing twelve months through Dec 2025 was 215.95% (up 2172436.0% YoY), and the annual figure for FY2025 was 246.06%, up 2443809.0%.
  • Net Margin for Q2 2025 was 22.87% at Traws Pharma, down from 26461.4% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 26461.4% in Q1 2025 to a low of 38248.21% in Q4 2024.
  • The 5-year median for Net Margin is 8027.79% (2023), against an average of 8863.29%.
  • The sharpest move saw Net Margin tumbled -3028036bps in 2024, then skyrocketed 3642275bps in 2025.
  • Year by year, Net Margin stood at 6719.64% in 2021, then plummeted by -52bps to 10239.29% in 2022, then increased by 22bps to 7967.86% in 2023, then tumbled by -380bps to 38248.21% in 2024, then soared by 100bps to 22.87% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 22.87%, 26461.4%, and 38248.21% for Q2 2025, Q1 2025, and Q4 2024 respectively.